Comprehensive pan-cancer analysis of the prognostic value of LOXL1

Abstract

Lysyl oxidase-like 1 (LOXL1) is widely expression in a variety of human tissues and can regulate cell differentiation. However, its role in a variety of tumors is still unclear. In this study, we aimed to study the role of LOXL1 across cancer. First, we downloaded clinical data from the UCSC and TCGA databases, and studied the mRNA expression levels of LOXL1 in TCGA_GTEx samples, TCGA samples and paired samples of TCGA, respectively. Subsequently, Kaplan-Meier analysis was performed for 33 kinds of tumors in TCGA, and LOXL1 was found to affect the prognosis. Clinical correlation analysis and univariate Cox regression analysis were carried out. In addition, the representative cancer renal clear cell carcinoma (KIRC)which had a sample size of more than 500 was selected to construct a nomgram to confirm the prognostic value of LOXL1 in cancer. The association between LOXL1 and immune cell infiltration was also determined. Finally, functional enrichment analysis was carried out to explore the potential signaling pathways which LOXL1 may participate. In summary, our research shows that LOXL1 is differentially expressed in many kinds of tumors and is related to the clinical outcome and immune microenvironment of many tumors. LOXL1 may participate in the occurrence and development of tumors through the PI3K-AKT signaling pathway and immune-related pathways.